Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JAN Codes Obtained by 90% of Medical Material Products
April 28, 2008
- Deliberations Focus on if Policy to Cut \1.1 Tri. Should Be Maintained
April 28, 2008
- Eliminate "Device Lag" by 2013: LDP's Working Team
April 28, 2008
- East Asian Pharmaceutical Regulatory Symposium 2008
April 28, 2008
- MEDICAL DEVICE NEWS IN BRIEF
April 28, 2008
- Pharmacovigilance Enhanced under PDUFA IV: Seminar
April 28, 2008
- Pre-Pandemic Vaccination of Healthcare Providers Approved
April 28, 2008
- NEW PRODUCTS／DS Pharma Biomedical to Launch Serum-Free Medium
April 28, 2008
- Korosho Preparing GL on Biosimilars
April 28, 2008
- Patient Participation Important in Schizophrenia Treatment
April 28, 2008
- REGULATORY NEWS IN BRIEF
April 28, 2008
- Lower Respiratory Tract Treatment Important in Elderly Asthma Patients
April 28, 2008
- Generic Makers Permitted to Use Original Makers' ADR Data without Permission
April 28, 2008
- Half of Hepatitis C Patients who Stop IFN Treatment Do so Because of Cost
April 28, 2008
- 70% of Doctors Permit Substitution for Oral Vitamins
April 28, 2008
- Janssen to Launch 4 New Products per Year
April 28, 2008
- Will Generics Take Off? (1)
April 28, 2008
- Takeda Bio Development Center to Apply for 2 Products by 2010
April 28, 2008
- GENERICS NEWS IN BRIEF
April 28, 2008
- Sanofi-aventis Starts Manufacturing Plavix in Japan
April 28, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…